Table 4.
Antitumor activity of trimellitimides derivatives 2–6 and 8 presented as growth inhibition percentages (GI %) over 59 subpanel tumour cell lines.
| Compound no. | 59 cancer cell lines assay in one dose 10.0 μM concentration: GI% |
|
|---|---|---|
| PCE* | Most sensitive cell lines* | |
| 2 | 3/59 | NSC Lung Cancer (NCI-H522: 12%), Renal Cancer (CAKI-1: 12%, UO-31: 13%). |
| 3 | 3/59 | NSC Lung Cancer (NCI-H522: 12%), CNS Cancer (SNB-75: 12%), Renal Cancer (UO-31: 16%). |
| 4 | 3/59 | Leukaemia (HL-60(TB): 18%), NSC Lung Cancer (NCI-H522: 16.0%), Renal Cancer (TK-10: 11%). |
| 5 | 5/59 | NSC Lung Cancer (HOP-92: 11%, NCI-H322M: 11%, NCI-H522: 11%), Renal Cancer (UO-31: 17%), Prostate Cancer (PC-3: 11%). |
| 6 | 2/59 | NSC Lung Cancer (HOP-92: 19%), CNS Cancer (SNB-75: 12%). |
| 8 | 3/59 | NSC Lung Cancer (HOP-92: 11%,), CNS Cancer (SNB-75: 13%), Renal Cancer (UO-31: 17%). |
| Imatinib | 20/59 | Leukaemia (MOLT-4: 18.0, PRMI-8226: 12.6, SR: 14.6), NSC Lung Cancer (EKVX: 15.7, NCI-H226: 10.6, NCI-H23: 17.1), Colon Cancer (HCT-116: 18.6, HCT-15: 11.5, HT29: 47.1), CNS Cancer (SF-295: 15.1, SF-539: 24.5, U251: 10.6), Melanoma (LOX IMVI: 11.6, SK-MEL-5: 22.3), Renal Cancer (A498: 13.7), Prostate Cancer (PC-3: 10.6, DU-145: 14.4), Breast Cancer (MDA-MB-231/ATCC: 11.2, T-47D: 18.6, MDA-MB-468: 29.1). |
*PCE: positive cytotoxic effect which is ratio between number of cell lines with percentage growth inhibition >10% and total number of cell lines.